Promises
1 promise
Promise Tracker
0 delivered, 0 close, 1 missed.
View Promises →Archean Chemical Industries Limited — Q3 FY26
Archean Chemical Industries reported a mixed Q3 FY26 with standalone revenue growing 12% YoY, but EBITDA declined 25% YoY to ₹69.9 crore, and PAT fell to ₹34.3 crore.
neutral
medium
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Archean Chemical Industries reported a mixed Q3 FY26 with standalone revenue growing 12% YoY, but EBITDA declined 25% YoY to ₹69.9 crore, and PAT fell to ₹34.3 crore. Industrial salt volumes recovered to 1.1 million tons, while bromine production remained constrained by operational issues, with a backlog of 6,500 tons. Bromine derivatives utilization is at 30-40%, with a target to reach 60-70% in FY27. SOP pilot trials are complete, with plant-scale trials expected in Q4. The semiconductor project (Systm) is progressing, with land allocation and groundbreaking completed. Risks include persistent delays in SOP and derivatives ramp-up, and potential margin pressure from rising bromine costs. Management acknowledged execution challenges but expressed confidence in recovery by FY27.
आर्कियन केमिकल इंडस्ट्रीज की तीसरी तिमाही के नतीजे मिले-जुले रहे। कंपनी की कमाई पिछले साल से 12% बढ़ी, लेकिन मुनाफा घट गया। मुख्य कारोबार से कमाई (EBITDA) 25% गिरकर ₹69.9 करोड़ रही, और शुद्ध मुनाफा (PAT) ₹34.3 करोड़ पर आ गया। औद्योगिक नमक की बिक्री बढ़कर 11 लाख टन हो गई, लेकिन ब्रोमीन उत्पादन में कमी रही और 6,500 टन का बकाया ऑर्डर है। ब्रोमीन से बने उत्पादों का उपयोग अभी 30-40% है, जिसे अगले साल 60-70% तक ले जाने का लक्ष्य है। SOP (पोटाश) के परीक्षण पूरे हो गए हैं और अगली तिमाही में बड़े पैमाने पर ट्रायल होंगे। सेमीकंडक्टर प्रोजेक्ट (Systm) में जमीन आवंटन और निर्माण शुरू हो गया है। जोखिमों में SOP और डेरिवेटिव्स में देरी और ब्रोमीन की बढ़ती लागत शामिल है। प्रबंधन ने चुनौतियाँ स्वीकार कीं, लेकिन अगले साल सुधार का भरोसा दिया।
Promises0 met · 1 missedRisks4 trackedTranscriptfull text
Research workspace
Focused Modules
Risks
4 risks
Risk Intelligence
Persistent delays in SOP and derivatives ramp-up
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Industrial salt sales volume
1.1M tons
+10% YoY
Q3 FY26 volume reverted to >1 million ton quarterly run rate, indicating strong demand.
Bromine backlog
6,500 tons
-2,500 tons QoQ
Backlog reduced from 9,500 tons as ~2,500 tons shipped; still significant.
Bromine derivatives utilization
30-40%
Flat QoQ
Utilization remains low; target is 60-70% in FY27 with new product pipeline.
Bromine production target
18,000 tons
Target for FY27
Management confident of reaching 18,000 ton run rate next year, up from current ~15,000.
What Changed vs Last Quarter
NEW
Bromine derivatives utilization target of 60-70% in FY27
Management expects to scale up bromine derivatives utilization from current 30-40% to 60-70% by end of FY27, driven by new product pipeline and customer approvals.
NEW
Bromine production to reach 18,000 tons run rate in FY27
Management stated they will be 'north of 18,000 tons' of bromine production next year, recovering from operational disruptions.
NEW
SOP plant-scale trials in Q4 FY26, meaningful contribution in H2 FY27
SOP pilot trials successful; plant-scale trials to commence in Q4 FY26, with meaningful revenue expected in second half of FY27.
NEW
Flame retardant project timeline of 12-18 months maintained
The flame retardant bromine project is under evaluation but remains on track for a 12-18 month timeline from Q2 FY26, targeting end of FY27.
DROPPED
Industrial salt volume guidance of 4.5 million tons for FY26
Management reiterated the full-year volume target despite Q2 shortfall due to monsoon, expecting to achieve it in H2.
DROPPED
Bromine derivatives capacity utilization to reach 50% by end of FY26
Current utilization is 30-35%; improvement expected as client approvals come through.
DROPPED
SOP commercial production to start post-monsoon FY27 (Q3 FY27)
Plant trials in Q4 FY26; full-fledged production expected after monsoon next year.
DROPPED
Semiconductor Phase 1 capex of ₹2,067 crore with 60-65% government support
Fiscal support agreement signing in advanced stage; project timeline ~30 months.
NEW RISK
Persistent delays in SOP and derivatives ramp-up
SOP and bromine derivatives have faced repeated delays; management acknowledged being 12-18 months behind on derivatives. Further delays could impact FY27 revenue expectations.
NEW RISK
Bromine production constraints from weather and brine quality
Operational disruptions from erratic monsoons and brine quality changes have constrained bromine output. While fixes are implemented, recurrence could limit volume growth.
NEW RISK
Margin pressure from rising bromine costs on derivatives
Increasing bromine prices are squeezing margins in the derivatives segment as cost pass-through is limited. This could persist if bromine prices remain elevated.
RISK GONE
Bromine production inefficiencies persist
Technical issues and erratic monsoon have led to lower bromine volumes; corrective measures may take time to yield results.
RISK GONE
Delays in Orin Hydrocarbons ramp-up
Acquisition challenges and slow client onboarding have pushed meaningful revenue contribution to FY27, 6 months behind schedule.
RISK GONE
Bromine derivatives revenue contribution remains low
Despite capex of ₹190 crore, utilization is only 30-35% due to slow client approvals and low crude prices affecting rig activity.
Fast read
Guidance and risk preview
Management expects to scale up bromine derivatives utilization from current 30-40% to 60-70% by end of FY27, driven by new product pipeline and cus...
SOP and bromine derivatives have faced repeated delays; management acknowledged being 12-18 months behind on derivatives.
View Risks →